Product license obtained for new radiopharmaceutical “Rakurs” (223Ra) based on radium 223 produced by Rosatom
The Russian Federal Medical and Biological Agency has obtained a product license for the import-substituting radiopharmaceutical “Rakurs” (223Ra). This medication is used in radioisotope therapy to treat patients with castration-resistant prostate cancer and bone metastases. The innovative product was developed at the Federal Scientific and Clinical Center for Medical Radiology and Oncology of Russian Federal…